Want to see ENTA full AI Analyst Report?
Enanta Pharmaceuticals (ENTA) Income Statement
Enanta Pharmaceuticals Income Statement
Last quarter (Q3 2026), Enanta Pharmaceuticals's total revenue was $14.36M, a decrease of 21.60% from the same quarter last year. In Q3, Enanta Pharmaceuticals's net income was $-19.50M. See Enanta Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Sep 25 | Sep 24 | Sep 23 | Sep 22 | Sep 21 |
|---|---|---|---|---|---|
| $ 65.32M | $ 67.64M | $ 79.20M | $ 86.16M | $ 97.07M | |
| $ 60.74M | $ 67.64M | $ 79.20M | $ 86.16M | $ 97.07M | |
| $ 146.09M | $ 189.33M | $ 216.41M | $ 210.00M | $ 206.65M | |
| Depreciation and Amortization | $ 5.09M | $ 2.34M | $ 2.37M | $ 2.97M | $ 3.33M |
| $ -70.78M | $ -104.51M | $ -123.48M | $ -119.22M | $ -104.25M | |
| $ -85.35M | $ -121.69M | $ -137.21M | $ -123.84M | $ -109.57M | |
| $ 1.80M | $ 3.90M | $ 6.21M | $ 1.66M | $ 1.99M | |
| $ -83.55M | $ -117.79M | $ -131.00M | $ -122.19M | $ -107.58M | |
| $ -81.89M | $ -116.05M | $ -133.82M | $ -121.75M | $ -79.00M | |
| Per Share Metrics | |||||
| Basic EPS | $ -3.84 | $ -5.48 | $ -6.38 | $ -5.91 | $ -3.92 |
| Diluted EPS | $ -3.84 | $ -5.48 | $ -6.38 | $ -5.91 | $ -3.92 |
| Weighted Average Shares Outstanding | 21.34M | 21.16M | 20.97M | 20.60M | 20.17M |
| Weighted Average Shares Outstanding (Diluted) | 21.34M | 21.16M | 20.97M | 20.60M | 20.17M |
Currency in USD
